Alterations of p14 ARF , p53 , and p73 Genes Involved in the E2F-1-mediated Apoptotic Pathways in Non-Small Cell Lung Carcinoma

Overexpression of E2F-1 induces apoptosis by both a p14 ARF - p53 - and a p73 -mediated pathway. p14 ARF is the alternate tumor suppressor product of the INK4a/ARF locus that is inactivated frequently in lung carci- nogenesis. Because p14 ARF stabilizes p53 , it has been proposed that the loss of p14 ARF is functionally equivalent to a p53 mutation. We have tested this hypothesis by examining the genomic status of the unique exon 1 b of p14 ARF in 53 human cell lines and 86 primary non-small cell lung carcinomas and correlated this with previously characterized alterations of p53 . Homozygous deletions of p14 ARF were detected in 12 of 53 (23%) cell lines and 16 of 86 (19%) primary tumors. A single cell line, but no primary tumors, harbored an intragenic mutation. The deletion of p14 ARF was inversely correlated with the loss of p53 in the majority of cell lines ( P 5 0.02), but this relationship was not maintained among primary tumors ( P 5 0.5). E2F-1 can also induce p73 via a p53 -independent apoptotic pathway. Although we did not observe inactivation of p73 by either mutation or DNA methylation, haploinsufficiency of p73 correlated positively with either p14 ARF or p53 mutation or both ( P 5 0.01) in primary non-small cell lung carcinomas. These data are consistent with the current model of p14 ARF and p53 interaction as a complex network rather than a simple linear pathway and indicate a possible role for an E2F-1 -mediated failsafe, p53 -independent, apoptotic pathway involving p73 in human lung carcinogenesis.

[1]  W. Kaelin,et al.  A common E2F-1 and p73 pathway mediates cell death induced by TCR activation , 2000, Nature.

[2]  David I. Smith,et al.  Role for the p53 homologue p73 in E2F-1-induced apoptosis , 2000, Nature.

[3]  M. Roussel,et al.  p53-independent functions of the p19(ARF) tumor suppressor. , 2000, Genes & development.

[4]  Erwin G. Van Meir,et al.  p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.

[5]  R. Jenkins,et al.  Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. , 2000, American journal of medical genetics.

[6]  M. Serrano,et al.  The INK4a/ARF locus in murine tumorigenesis. , 2000, Carcinogenesis.

[7]  B. Gusterson,et al.  A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.

[8]  M. Roussel,et al.  Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex , 2000, Molecular and Cellular Biology.

[9]  R. Sclafani,et al.  Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein , 2000, Oncogene.

[10]  O. Tachibana,et al.  Alterations of the INK 4 a / ARF Locus in Human Intracranial Germ Cell Tumors 1 , 2000 .

[11]  J. Herman,et al.  Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. , 2000, Cancer research.

[12]  K. Ichimura,et al.  Deregulation of the p 14 ARF / MDM 2 / p 53 Pathway Is a Prerequisite for Human Astrocytic Gliomas with G 1S Transition Control Gene Abnormalities 1 , 2000 .

[13]  D. Germain,et al.  Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilization with D-type cyclins , 1999, Oncogene.

[14]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[15]  J. Haveman,et al.  Inactivation of p53 and of pRb protects human colorectal carcinoma cells against hyperthermia-induced cytotoxicity and apoptosis , 1999, Journal of Cancer Research and Clinical Oncology.

[16]  E. Brambilla,et al.  Alterations of expression of Rb, p16INK4A and cyclin D1 in non‐small cell lung carcinoma and their clinical significance , 1999, The Journal of pathology.

[17]  J. Herman,et al.  Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. , 1999, Cancer research.

[18]  A. Levine,et al.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. H. Randle,et al.  Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.

[20]  D. Tindall,et al.  Mutation and expression analysis of the p73 gene in prostate cancer , 1999, The Prostate.

[21]  M. Urioste,et al.  Analysis of the INK4a/ARF locus in non-Hodgkin’s lymphomas using two new internal microsatellite markers , 1999, Leukemia.

[22]  Toshiaki Tanaka,et al.  p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts , 1999, Oncogene.

[23]  D. Germain,et al.  Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer , 1999, Oncogene.

[24]  D. Tindall,et al.  Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.

[25]  F. McKeon,et al.  p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent , 1999, Oncogene.

[26]  T. Halazonetis,et al.  Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. , 1998, The American journal of pathology.

[27]  W. Stolz,et al.  Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas , 1998, Melanoma research.

[28]  M. Tschan,et al.  Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression , 1998, Oncogene.

[29]  C. Sherr,et al.  Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.

[30]  Karen H. Vousden,et al.  p14ARF links the tumour suppressors RB and p53 , 1998, Nature.

[31]  J. Benítez,et al.  Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. , 1998, The American journal of pathology.

[32]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[33]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[34]  L. Chin,et al.  The INK4a/ARF tumor suppressor: one gene--two products--two pathways. , 1998, Trends in biochemical sciences.

[35]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Liotta,et al.  Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. , 1998, Cancer research.

[37]  Y. Hosokawa,et al.  Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele‐specific expression , 1998, Genes, chromosomes & cancer.

[38]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[39]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[40]  V. Gouyer,et al.  Mechanisms of p16INK4A inactivation in non small-cell lung cancers , 1998, Oncogene.

[41]  S. Srivastava,et al.  Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells , 1998, Oncogene.

[42]  L. Liotta,et al.  Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. , 1998, Human pathology.

[43]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[44]  C. Harris,et al.  Serum, plasma and paraffin-embedded tissues as sources of DNA for studying cancer susceptibility genes. , 1997, Carcinogenesis.

[45]  M. Tucker,et al.  Screening for CDKN2A mutations in hereditary melanoma. , 1997, Journal of the National Cancer Institute.

[46]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[47]  D. Niewoehner,et al.  Rb and p16INK4a expression in resected non-small cell lung tumors. , 1996, Cancer research.

[48]  G. Peters,et al.  Perturbation of cell cycle regulators in human cancer. , 1996, Cancer surveys.

[49]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[50]  C. D. Edwards,et al.  A novel p16INK4A transcript. , 1995, Cancer research.

[51]  S. Tavtigian,et al.  Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.

[52]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[53]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[54]  J. Jett,et al.  Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. , 1995, Carcinogenesis.

[55]  C. D. Edwards,et al.  Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.

[56]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[57]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[58]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[59]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[60]  D. Sidransky,et al.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.

[61]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[62]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[63]  J. Minna The molecular biology of lung cancer pathogenesis. , 1993, Chest.

[64]  P. Friedman,et al.  Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. , 1992, Genes & development.

[65]  W. Lee,et al.  Inactivation of the retinoblastoma susceptibility gene in human breast cancers. , 1988, Science.

[66]  S. Lowe,et al.  The p 53 and p 73 : seeing double ? , 2022 .